Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

BACKGROUND: Patients with treatment-naive advanced urothelial cancer (UC) Ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. OBJECTIVE: To evaluate the safety and antitumor activity of first-line pembrolizumab in subg...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivas, Petros, Plimack, Elizabeth R., Balar, Arjun V., Castellano, Daniel, O’Donnell, Peter H., Bellmunt, Joaquim, Powles, Thomas, Hahn, Noah M., de Wit, Ronald, Bajorin, Dean F., Ellison, Misoo C., Frenkl, Tara L., Godwin, James L., Vuky, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246631/
https://www.ncbi.nlm.nih.gov/pubmed/32423837
http://dx.doi.org/10.1016/j.euo.2020.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246631/
https://www.ncbi.nlm.nih.gov/pubmed/32423837
http://dx.doi.org/10.1016/j.euo.2020.02.009

Ejemplares similares